Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410591 | 0.84 | PKM (0.41) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL277445 | 0.78 | PLK1 (0.51) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL13339311 | 0.77 | NPC1 (0.46) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL15459742 | 0.75 | NPC1 (0.54) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL12410190 | 0.75 | KMT2A (0.64) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL11955602 | 0.74 | NPC1 (0.41) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL12410462 | 0.73 | CYP4F2 (0.41) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12410588 | 0.73 | GAA (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL12421889 | 0.73 | NPC1 (0.49) | NPC1KMT2ARAB9AL3MBTL1HPGD | |
| SCHEMBL13944298 | 0.72 | PLK1 (0.60) | KMT2AHPGDSMN1; SMN2MGLLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8449872-B2 | Polymer conjugates of nesiritide peptides | NEKTAR THERAPEUTICS (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165111-A1 | POLYMER CONJUGATES OF NESIRITIDE PEPTIDES | NGLY1, IAPP, NPSR1 | NPC1 759/4885KMT2A 3922/4885RAB9A 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.